Literature DB >> 1715669

The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin.

G R Skuse1, B A Kosciolek, P T Rowley.   

Abstract

von Recklinghausen neurofibromatosis (NF1) is the most common hereditary syndrome predisposing to neoplasia. NF1 is an autosomal dominant disease caused by a single gene which maps to chromosome 17q11.2. The most common symptomatic manifestation of NF1 is the benign neurofibroma. Our previous studies of tumors in NF1, studies which detected a loss of heterozygosity for DNA markers from the NF1 region of chromosome 17 in malignant tumors, did not detect a loss in neurofibromas. We report here that a more extensive study, including the analysis of neurofibromas from 19 unrelated NF1 patients by using seven probes, failed to detect a single instance of loss of heterozygosity. This finding suggests that neurofibromas are either polyclonal or monoclonal in origin but arise by a mechanism different from that of NF1 malignancies. In order to investigate the first possibility, we analyzed neurofibromas from female NF1 patients by using an X chromosome-specific probe, from the phosphoglycerokinase (PGK) gene, which detects an RFLP. The detected alleles carry additional recognition sites for the methylation-sensitive enzyme HpaII, so that the allele derived from the active X chromosome is digested by HpaII while the one from the hypermethylated, inactive X chromosome is not. We analyzed neurofibromas from 30 unrelated females with NF1. Eight patients were heterozygous for the PGK RFLP. By this assay, neurofibromas from all eight appeared monoclonal in origin. These results suggest that benign neurofibromas in NF1 arise by a mechanism that is different from that of malignant tumors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1715669      PMCID: PMC1683134     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  41 in total

1.  SELECTION IN MAMMALIAN MOSAIC CELL POPULATIONS.

Authors:  S M GARTLER; D LINDER
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1964

2.  DISTRIBUTION OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE ELECTROPHORETIC VARIANTS IN DIFFERENT TISSUES OF HETEROZYGOTES.

Authors:  D LINDER; S M GARTLER
Journal:  Am J Hum Genet       Date:  1965-05       Impact factor: 11.025

3.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

4.  Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17.

Authors:  G R Skuse; B A Kosciolek; P T Rowley
Journal:  Genes Chromosomes Cancer       Date:  1989-09       Impact factor: 5.006

5.  A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations.

Authors:  R M Cawthon; R Weiss; G F Xu; D Viskochil; M Culver; J Stevens; M Robertson; D Dunn; R Gesteland; P O'Connell
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

Review 6.  X-chromosome inactivation and developmental patterns in mammals.

Authors:  M F Lyon
Journal:  Biol Rev Camb Philos Soc       Date:  1972-01

7.  Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene.

Authors:  B R Seizinger; G A Rouleau; L J Ozelius; A H Lane; A G Faryniarz; M V Chao; S Huson; B R Korf; D M Parry; M A Pericak-Vance
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

8.  Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; A P Feinberg
Journal:  Science       Date:  1985-02-08       Impact factor: 47.728

9.  Regional mapping panel for human chromosome 17: application to neurofibromatosis type 1.

Authors:  P van Tuinen; D C Rich; K M Summers; D H Ledbetter
Journal:  Genomics       Date:  1987-12       Impact factor: 5.736

10.  Hemizygous expression of glucose-6-phosphate dehydrogenase in erythrocytes of heterozygotes for the Lesch-Nyhan syndrome.

Authors:  W L Nyhan; B Bakay; J D Connor; J F Marks; D K Keele
Journal:  Proc Natl Acad Sci U S A       Date:  1970-01       Impact factor: 11.205

View more
  7 in total

1.  Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components.

Authors:  T Watanabe; Y Oda; S Tamiya; K Masuda; M Tsuneyoshi
Journal:  J Clin Pathol       Date:  2001-08       Impact factor: 3.411

Review 2.  Clinical and genetic patterns of neurofibromatosis 1 and 2.

Authors:  N K Ragge
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

3.  Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours.

Authors:  H Chen; S Hirota; K Isozaki; H Sun; A Ohashi; K Kinoshita; P O'Brien; L Kapusta; I Dardick; T Obayashi; T Okazaki; Y Shinomura; Y Matsuzawa; Y Kitamura
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

4.  Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras.

Authors:  M R Johnson; A T Look; J E DeClue; M B Valentine; D R Lowy
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

5.  Clonal analysis of human astrocytomas.

Authors:  R P Morse; B T Darras; Z Ye; J K Wu
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Skin-derived precursor cells as an in vitro modelling tool for the study of type 1 neurofibromatosis.

Authors:  Araika Gutiérrez-Rivera; Haizea Iribar; Anna Tuneu; Ander Izeta
Journal:  Stem Cells Int       Date:  2012-04-01       Impact factor: 5.443

7.  Neurofibromin-deficient fibroblasts fail to form perineurium in vitro.

Authors:  T Rosenbaum; Y L Boissy; K Kombrinck; C I Brannan; N A Jenkins; N G Copeland; N Ratner
Journal:  Development       Date:  1995-11       Impact factor: 6.868

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.